ONESOURCEPharmaceuticals
OneSource Specialty Pharma Inc — Profit & Loss Statement
₹1473.30
+8.47%
OneSource Specialty Pharma Inc Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Tax Effect Of Unusual Items | -33.25 Cr | 0.00 | 0.00 |
| Tax Rate For Calcs | 0.30 | 0.00 | 0.00 |
| Normalized EBITDA | 483.99 Cr | -64.93 Cr | -116.69 Cr |
| Total Unusual Items | -110.84 Cr | -115.94 Cr | -144.75 Cr |
| Total Unusual Items Excluding Goodwill | -110.84 Cr | -115.94 Cr | -144.75 Cr |
| Net Income From Continuing Operation Net Minority Interest | -17.28 Cr | -365.70 Cr | -415.64 Cr |
| Reconciled Depreciation | 273.88 Cr | 95.38 Cr | 114.10 Cr |
| Reconciled Cost Of Revenue | 435.03 Cr | 70.51 Cr | 20.41 Cr |
| EBITDA | 373.14 Cr | -180.87 Cr | -261.44 Cr |
| EBIT | 99.26 Cr | -276.25 Cr | -375.54 Cr |
| Net Interest Income | -166.32 Cr | -89.45 Cr | -45.97 Cr |
| Interest Expense | 166.32 Cr | 89.45 Cr | 40.11 Cr |
| Normalized Income | 60.31 Cr | -249.75 Cr | -270.89 Cr |
| Net Income From Continuing And Discontinued Operation | -17.97 Cr | -391.17 Cr | -799.83 Cr |
| Total Expenses | 1.25K Cr | 336.45 Cr | 254.60 Cr |
| Diluted Average Shares | 11.03 Cr | 4.15 Cr | 4.15 Cr |
| Basic Average Shares | 11.03 Cr | 4.15 Cr | 4.15 Cr |
| Diluted EPS | -1.63 | -94.15 | -192.51 |
| Basic EPS | -1.63 | -94.15 | -192.51 |
| Diluted NI Availto Com Stockholders | -17.97 Cr | -391.17 Cr | -799.83 Cr |
| Net Income Common Stockholders | -17.97 Cr | -391.17 Cr | -799.83 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 |
| Net Income | -17.97 Cr | -391.17 Cr | -799.83 Cr |
| Net Income Including Noncontrolling Interests | -17.97 Cr | -391.17 Cr | -799.83 Cr |
| Net Income Discontinuous Operations | -0.69 Cr | -25.47 Cr | -384.19 Cr |
| Net Income Continuous Operations | -17.28 Cr | -365.70 Cr | -415.64 Cr |
| Tax Provision | -49.78 Cr | 0.00 | 0.00 |
| Pretax Income | -67.07 Cr | -365.70 Cr | -415.64 Cr |
| Other Non Operating Income Expenses | 17.47 Cr | 4.22 Cr | — |
| Special Income Charges | -110.84 Cr | -115.94 Cr | -144.75 Cr |
| Restructuring And Mergern Acquisition | 110.84 Cr | 0.00 | — |
| Net Non Operating Interest Income Expense | -166.32 Cr | -89.45 Cr | -45.97 Cr |
| Interest Expense Non Operating | 166.32 Cr | 89.45 Cr | 40.11 Cr |
| Operating Income | 192.63 Cr | -164.53 Cr | -215.88 Cr |
| Operating Expense | 817.19 Cr | 265.94 Cr | 234.19 Cr |
| Other Operating Expenses | 328.05 Cr | 110.29 Cr | 58.39 Cr |
| Depreciation And Amortization In Income Statement | 273.88 Cr | 76.29 Cr | 65.68 Cr |
| Depreciation Income Statement | 273.88 Cr | 76.29 Cr | 65.68 Cr |
| Gross Profit | 1.01K Cr | 101.41 Cr | 18.30 Cr |
| Cost Of Revenue | 435.03 Cr | 70.51 Cr | 20.41 Cr |
| Total Revenue | 1.44K Cr | 171.92 Cr | 38.71 Cr |
| Operating Revenue | 1.44K Cr | 171.92 Cr | 38.71 Cr |
| Interest Income | — | 1.92 Cr | 1.58 Cr |
| Rent Expense Supplemental | — | 2.69 Cr | 1.08 Cr |
| Other Special Charges | — | 115.94 Cr | -0.91 Cr |
| Write Off | — | 0.07 Cr | 49.63 Cr |
| Impairment Of Capital Assets | — | 0.00 | 96.03 Cr |
| Total Other Finance Cost | — | 4.05 Cr | 7.44 Cr |
| Interest Income Non Operating | — | 1.92 Cr | 1.58 Cr |
| Selling General And Administration | — | 22.87 Cr | 32.76 Cr |
| Selling And Marketing Expense | — | 0.90 Cr | 9.33 Cr |
| General And Administrative Expense | — | 21.96 Cr | 23.43 Cr |
| Rent And Landing Fees | — | 2.69 Cr | 1.08 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on OneSource Specialty Pharma Inc
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.